LONDON, June 28 (Reuters) - Britain's Shire Plc is challenging its sales force to capture 50 percent of the U.S. market for treating attention deficit hyperactivity disorder (ADHD) by early next ...

New Orleans – November 16, 2006 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that a single once-daily morning dose of the investigational amphetamine compound SPD465, extended ...

21 Jun 2007 - Basingstoke, U.K., and Philadelphia, U.S. – June 21, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food ...

To coincide with ADHD Awareness Month, Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the winners of the 2016 Excellence in ADHD Patient Group Awards. The awards celebrate outstanding work by ...

LONDON, Feb 9 (Reuters) - Europe's scepticism over attention deficit hyperactivity disorder (ADHD) is starting to lift, opening up a market that could grow to $1 billion-a-year by 2012-13, British ...

Drug maker Shire plc will pay $48 million to Impax Laboratories Inc. to settle a lawsuit around Impax's generic version of the ADHD drug Adderall XR. Drug maker Shire plc will pay $48 million to Impax ...

SAN FRANCISCO (MarketWatch) -- Shire Plc on Friday said it has submitted a new drug application with the Food and Drug Administration for SPD465, an investigational ...

BOSTON (MarketWatch) -- Shire plc's partner Noven Pharmaceuticals Inc. said early Monday that Shire has withdrawn its application in Europe for its Daytrana patch to treat attention deficit ...